Making the discoveries that defeat cancer

  • Home |
  • About Us  |
  • Research  |
  • Enterprise  |
  • Education  |
  • Jobs  |
  • Support Us  |
  • News  |
  • Contact Us
  • Home »
  • News »
  • Recent Featured Articles »
  • Featured Article Archive

News

  • Cancer Voices
  • Press Release Archive
  • PR Contacts
  • Recent Featured Articles
  • Research Highlights

Landmark Ovarian Cancer Discovery as Scientists Unveil High Risk Gene

Cancer Research UK-funded scientists have discovered that women who carry a faulty copy of a gene called RAD51D have almost a one in 11 chance of developing ovarian cancer, the most significant ovarian cancer gene discovery for more than a decade, reveals a study in Nature Genetics* today.

 

The team at The Institute of Cancer Research (ICR) examined DNA from women from 911 families with ovarian and breast cancer and compared differences in DNA with a control group of 1060 people from the general population.

 

The team discovered eight gene faults in the RAD51D gene in women with cancer, compared with one in the control group.

 

Ovarian cancer is the fifth most common cancer in women - around 6,500 cases are diagnosed annually in the UK. The researchers estimate that RAD51D gene faults are present in almost one per cent of women with ovarian cancer - around 50 UK women each year.

 

Around one woman in 70 in the general population is at risk of developing ovarian cancer, but for those with a RAD51D gene fault this risk is increased to one in 11 – making these women six times more likely to develop the disease.

Recent Featured Articles

  • Breast cancer patients with gene fault at increased risk of disease returning
  • Tackling cancer’s biggest challenge
  • Untangling the evolution of cancer
  • Combining imaging and gene analysis could transform breast cancer diagnosis
  • Single agent doxorubicin therapy for sarcoma
  • The ICR identity project
  • New drug type could boost chemotherapy
  • High quality of our clinical trials confirmed
  • Clinical trial tests new combination treatment for advanced prostate cancer
  • Funding injection into prostate cancer research
  • The ICR turns up the heat on tumour cells
  • The promise of immunotherapy - and bridging the funding gap
  • The Story of Abiraterone
  • Featured Article Archive

Featured Article Archive

  • Europe-wide cancer research competition winners
  • ICR drug discovery highlighted for patient impact
  • Prostate Cancer Progress
  • Vital Funding Continues for Cancer Research
  • New Type of Hormone Therapy Extends Prostate Cancer Patients’ Lives
  • Non-Surgical Cancer Treatment
  • Educating the Next Generation of Researchers
  • Novel BRAF Inhibitors
  • NCRI Cancer Conference 2011
  • Paul Workman features in BBC Radio 4 science special
  • Professor Philip Lawley
  • Professor Ian Judson on BBC Radio 4
  • Video: New protein stretches 2.5 times its length
  • ICR Scientific Image Competition
  • The Art of Structural Biology
  • canSAR Drug Discovery Database Launched
  • Myeloma IX Study
  • The Centre for Molecular Pathology
  • HPC: A Revolution in Cancer Research
  • BBC World highlights the future of personalised medicine in the UK
  • Testing New Radiotherapy Techniques for Breast Cancer
  • NICE issues draft guidance on abiraterone acetate
  • Buzz grows around PI3K drug
  • Global award for cancer drug success
  • Progress: Promising new targeted drugs revealed
  • The ICR features in BBC documentary Horizon
  • Abiraterone on the NHS


Last updated: 15 February 2012

  • Contacts  | 
  • Privacy  | 
  • Terms and Conditions  | 
  • Accessibility  | 
  • Feedback  | 
  • Cookies  | 
  • Status
  • ICR News RSS Feed
  • Find us on Facebook
  • Follow us on Twitter